A preparation of autologous T-lymphocytes that have been genetically modified to express a chimeric antigen receptor (CAR) targeting natural-killer group 2, member D ligands (NKG2DLs), with potential immunostimulating and antineoplastic activities. Upon administration, autologous anti-NKG2DLs CAR-T cells LEU011 specifically recognize and induce selective toxicity in tumor cells expressing NKG2DLs. Ligands for NKG2D, such as MHC class I chain-related protein A (MICA), MICB, and members of the UL16-binding proteins (ULBP)/retinoic acid early transcript 1 (RAET1) family, are overexpressed on various cancer cell types, but are not expressed on most normal, healthy cells.